[PDF] Top 20 Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta- analysis based on 15 studies

... effect evaluation of clinical new drug involves the ethical and moral risk, therefore most of studies included in this analysis are non-randomized current controlled trials ...eleven ... See full document

... the efficacy and safety profile of adding celecoxib to systemic therapy in only patients with advanced NSCLC; 3) the eligible patients enrolled were adult patients with Eastern Coopera- tive Oncology Group ... See full document

... Results based on indirect comparisons suggested a significantly reduced risk of drug-related grade 3–5 AEs with NIVO ...the non-uniform occurrence rate of these events in the DOC arms (range: ...favourable ... See full document

... interim analysis, in which only 30 ...updated analysis showed that the BE regimen produced a shorter PFS and a higher inci- dence of death than ...the small valid sample size in this ...several ... See full document

... subgroup analysis that was based on the type of COX-2 inhibitors and treatment line, 1-year SR also did not change between COX-2 inhibitors plus che- motherapy and chemotherapy ...Three studies 10–12 ... See full document

... valuable evaluation of ...of safety. The most common TRAEs in the original studies were fatigue, hematological adverse events (AEs), and gas- trointestinal ... See full document

... three studies, 29,34,35 and three others did show the Markov model ...Two studies 33,37 manifested the formula of the transitioning prob- abilities speci fi cally from each stage to the next, while most ... See full document

... risk–benefit analysis of docetaxel, several clinical trials have investigated the effectiveness and safety between docetaxel and pemetrexed or docetaxel and vinca ...have small samples, which supply ... See full document

... gastric cancer (GC) in China. Nevertheless, its therapeutic efficacy against other types of advanced solid tumors remains ...This meta-analysis examines the short-term efficacy and ... See full document

... several studies have reported on the efficacy and safety of Endostar in the treatment of advanced lung ...This systematic review was per- formed to quantify better the benefits and ... See full document

... Subgroup analysis was also conducted based on matched and un- matched cohort studies, if ...among studies was considered to be statistically ...the studies was identi- fied by ... See full document

... a small study of 11 biopsied ceritinib-resistant tumors (two of the 11 obtained from dif- ferent tumors in the same patient), five samples were found to harbor either F1174C or G1202R, two mutations that were also ... See full document

... variability attributable to statistical heterogeneity between trials. If heterogeneity existed, data were analyzed using a random-effects model based on DerSimonian and Laird method. In the absence of ... See full document

... OR (“Immune checkpoint” [All Fields]) OR (“Immune checkpoint inhibitor” [All Fields]). We used this search strategy to search PubMed (https://www.ncbi.nlm.nih.gov/ pubmed), Embase (https://www.embase.com/login), and ... See full document

... This systematic review and meta-analysis resumes the available data from published phase III RCT regarding the OS benefit of anti-PD-1/anti-PD-L1 agents versus docetaxel in patients with progressive ... See full document

... The use of 4 types of therapy administered sequentially was only possible due to the good physical condition of the patient, which suggested that he could tolerate any adverse effects. During the course of WBRT, the ... See full document

... Comprehensive Cancer Network guidelines recommended new strategies for patients resistant to crizotinib according to response evaluation criteria in solid tumors ...An analysis of 194 patients from ... See full document

... multidisciplinary lung cancer programs to help integrate all of the specialties involved in NSCLC can avert undertreatment of the ...influence evaluation, manage- ment, or treatment of NSCLC in the ... See full document

... that icotinib had a favorable safety profile, with the most common adverse reactions being rash and diarrhea (both were grade I or II), with incidence rates of 34% (36/103) and 11% (12/103), ...of ... See full document

... Eligible studies were required to meet the following criteria: 1) articles with prospective trials investigating nivolumab on advanced NSCLC patients; 2) studies reporting any of the following information: ... See full document